Indications and uses
For the temporary relief of nasal congestion due to: a cold hay fever upper respiratory allergies Relieves symptoms of nasal discomfort caused by dryness and sinus pressure.
For the temporary relief of nasal congestion due to: a cold hay fever upper respiratory allergies Relieves symptoms of nasal discomfort caused by dryness and sinus pressure.
Children 6 to under 12 years of age (with adult supervision): 1- 2 sprays in each nostril not more often than every 8 to 10 hours. Children 2 to under 6 years of age (with adult supervision): 1- 2 sprays in each nostril not more often than every 8 to 10 hours. Children under 2 years of age: consult a doctor. Use only recommended amount Do not exceed 3 doses in any 24-hour period. Use Instructions: place a small am...
Store between 68° and 77° F (20°- 25° C)
| Active Ingredients Xylometazoline Hydrochloride 0.05% | Purpose Nasal Decongestant |
For the temporary relief of nasal congestion due to:
Relieves symptoms of nasal discomfort caused by dryness and sinus pressure.
Ask a doctor before use if you have
Stop use and ask a doctor if symptoms persist.
If swallowed, get medical help or contact Poison Control Center right away.
Use Instructions: place a small amount in each nostril and inhale well back into the nasal passages.
Store between 68° and 77° F (20°- 25° C)
purified seawater, potassium dihydrogen phosphate
1-888-353-AQUA
76260-107-05
Distributed by:
JGL North America LLC
New York, NY 10024
www.aquamaris.com
Made in Croatia
jgl
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 76260-107-05 | 2023-02-24 | C162847 | 48780-1 | 9855e2a2-42e7-60a7-e053-dbdaa90a05bd | AQUA MARIS ® xylometazoline HCl 0.05% + purified seawater |
| 76260-107-05 | 2019-11-27 | C162847 | 48780-1 | 9855e2a2-42e7-60a7-e053-dbdaa90a05bd | AQUA MARIS ® xylometazoline HCl 0.05% + purified seawater |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| XYLOMETAZOLINE HYDROCHLORIDE | ACTIVE INGREDIENT | X5S84033NZ | 2 | |
| XYLOMETAZOLINE | ACTIVE MOIETY | WPY40FTH8K | 2 | |
| POTASSIUM PHOSPHATE, MONOBASIC | INACTIVE INGREDIENT | 4J9FJ0HL51 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 76260-107 | 76260-107-05 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| XYLOMETAZOLINE HYDROCHLORIDE | X5S84033NZ | ACTIB |
| WATER | 059QF0KO0R | IACT |
| POTASSIUM PHOSPHATE, MONOBASIC | 4J9FJ0HL51 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 272 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION / INTRA-ARTICULAR | 0.3 %w/v | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SOLUTION / NASAL | 680 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 110 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION / SUBCUTANEOUS | 8 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SUSPENSION / ORAL | 50 mg/5ml | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION / INTRAMUSCULAR | 0.3 %w/v | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SOLUTION / ORAL | 287 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION, SOLUTION / INTRAVENOUS | 1.36 %w/v | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SPRAY / NASAL | 3 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SOLUTION / AURICULAR (OTIC) | 0.2 %w/w | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SUSPENSION / OPHTHALMIC | 0.44 %w/w | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | CAPSULE, COATED PELLETS / ORAL | 272 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | TABLET / ORAL | 25 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION / INTRAVENOUS | 68 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SOLUTION / OPHTHALMIC | 0.2 %w/w | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | SYRUP / ORAL | 19 mg | ||
| POTASSIUM PHOSPHATE, MONOBASIC | MONOBASIC POTASSIUM PHOSPHATE | 4J9FJ0HL51 | INJECTION, SOLUTION / INTRAVESICAL | 29.2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f56fdcfe-bb65-2813-e053-2995a90a8ca7 | 0c1f137f-2318-4551-9792-d25542e4d953 | 2023-02-24 | Warnings | 0c1f137f-2318-4551-9792-d25542e4d953 |
Adverse event summaries are temporarily unavailable. Other product information remains available.